# US 2023/0068949 A1 · New mesothelin specific chimeric antigen receptors (CAR) for solid tumors cancer immunotherapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0068949 A1
- Document ID: US20230068949A1
- Status: Published application
- Kind: A1
- Application number: 17/788,133
- Filed: 2020-12-22
- Published: 2023-03-02
- Earliest claimed: 2019-12-23
- Assignees: Cellectis
- Applicants: Cellectis
- Inventors: Cecile SCHIFFER-MANNIOUI; Philippe DUCHATEAU
- Web page: https://patentgrep.com/patent/US20230068949A1

## CPC

- C07K 14/70521: {CD28, CD152}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4255: {Mesothelin [MSLN]}
- A61P 35/00: Antineoplastic agents
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70517: {CD8}
- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 16/30: from tumour cells
- C12N 5/0636: {T lymphocytes}
- C12N 15/907: {in mammalian cells}
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/54: Pancreas
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2319/02: containing a signal sequence
- C07K 2319/03: containing a transmembrane segment
- C12N 2510/00: Genetically modified cells
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to engineered immune cells expressing new mesothelin (MLSN) specific chimeric antigen receptors (anti-mesothelin CAR) and their use in the treatment of solid tumors, particularly suited for allogeneic cell immunotherapy.

## Claims

### Claim 1

A mesothelin specific chimeric antigen receptor (CAR) comprising at least:
an extracellular ligand binding-domain comprising VH and VL from a monoclonal anti-mesothelin antibody;
a transmembrane domain; and
a cytoplasmic domain comprising a CD3 zeta signalling domain and a co-stimulatory domain
wherein said extra cellular ligand binding-domain is directed against the MSLN antigen polypeptide region SEQ ID NO:25.

### Claim 2 (depends on 1)

A mesothelin specific chimeric antigen receptor (CAR) according to claim 1, wherein said extra cellular ligand binding-domain comprises:
a variable heavy VH chain comprising CDRs from the antibody Meso1 having respectively at least 90% identity with SEQ ID NO:3 (CDRH1-Meso1), SEQ ID NO:4 (CDRH2-Meso1) and SEQ ID NO:5 (CDRH3-Meso1), and
a variable heavy VL chain comprising CDRs from the antibody Meso1 having respectively at least 90% identity with SEQ ID NO:6 (CDRL1-Meso1), SEQ ID NO:7 (CDRL2-Meso1) and SEQ ID NO:8 (CDRL3-Meso1).

### Claim 3 (depends on 1)

A mesothelin specific chimeric antigen receptor according to claim 1, wherein said extra cellular ligand binding-domain comprises VH and VL chains having at least 80%, preferably at least 90%, more preferably at least 95%, and even more preferably at least 99% sequence identity respectively with SEQ ID NO:9 (Meso1-VH) and SEQ ID NO:10 (Meso1-VL).

### Claim 4 (depends on 1, 2, 3)

A mesothelin specific chimeric antigen receptor (CAR) according to any one of claims 1 to 3, wherein said transmembrane domain is from the transmembrane region(s) of the alpha, beta or zeta chain of the T-cell receptor, PD-1, 4-1BB, OX40, ICOS, CTLA-4, LAG3, 2B4, BTLA4, TIM-3, TIGIT, SIRPA, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137 or CD154.

### Claim 5 (depends on 4)

A mesothelin specific chimeric antigen receptor (CAR) according to claim 4, wherein the transmembrane domain shares at least 80%, preferably at least 90%, more preferably at least 95%, and even more preferably at least 99% sequence identity with SEQ ID NO.6 from CD8α.

### Claim 6 (depends on 1, 2, 3, 4, 5)

A mesothelin specific chimeric antigen receptor (CAR) according to any one of claims 1 to 5, further comprising a hinge between the extracellular ligand-binding domain and the transmembrane domain.

### Claim 7 (depends on 6)

A mesothelin specific chimeric antigen receptor (CAR) according to claim 6, wherein said hinge is selected from CD8α hinge, IgG1 hinge and FcγRIIIα hinge.

### Claim 8 (depends on 7)

A mesothelin specific chimeric antigen receptor (CAR) according to claim 7, wherein the hinge shares at least 80%, preferably at least 90%, more preferably at least 95%, and even more preferably at least 99% sequence identity, respectively with SEQ ID NO.16 (CD8α).

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

A mesothelin specific CAR according to anyone of claim 1 to 8, wherein said CAR has a polypeptide structure comprising an CD8α hinge having at least 80% identity with the amino acid sequence set forth in SEQ ID NO.16 and a CD8α transmembrane domain having at least 80% identity with the amino acid sequence set forth in SEQ ID NO.17.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A mesothelin specific CAR according to anyone of claim 1 to 9, further comprising a safety switch comprising an epitope selected from Table 5.

### Claim 11 (depends on 10)

A mesothelin specific CAR according to claim 10, wherein said safety switch which comprises the epitope CPYSNPSLC (SEQ ID NO:26) that is specifically bound by rituximab.

### Claim 12 (depends on 10, 11)

A mesothelin specific CAR according to claim 10 or 11, wherein said CAR comprises a safety switch R2 that has at least 90% identity with SEQ ID NO:15.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

A mesothelin specific chimeric antigen receptor according to any one of claims 1 to 12, wherein said CAR comprises a co-stimulatory domain from 4-1BB or CD28.

### Claim 14 (depends on 13)

A mesothelin specific CAR according to claim 13, wherein said co-stimulatory domain is from 4-1 BB and/or has at least 80% identity with SEQ ID NO:18.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

A mesothelin specific CAR according to any one of claims 1 to 14, wherein said CD3 zeta signalling domain has at least 80% identity with SEQ ID NO:19.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

A mesothelin specific CAR according to any one of claims 1 to 15, further comprising a signal peptide.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

A mesothelin specific chimeric antigen receptor (CAR) according to any one of claims 1 to 16, wherein the CAR is a single-chain polypeptide.

### Claim 18 (depends on 17)

A mesothelin specific chimeric antigen receptor (CAR) according to claim 17, wherein said CAR has at least 80%, preferably at least 90%, more preferably at least 95%, and even more preferably at least 99% overall amino acid sequence identity with SEQ ID NO:21 (Meso1 CAR) or SEQ ID NO:22 (Meso1-R2 CAR).

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

A polynucleotide encoding a chimeric antigen receptor according to any one of claims 1 to 18.

### Claim 20 (depends on 19)

An expression vector comprising a polynucleotide of claim 19.

### Claim 21 (depends on 19, 20)

An engineered immune cell comprising a polynucleotide according to claim 19 or an expression vector according to claim 20.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

An engineered immune cell expressing at the cell surface membrane a mesothelin specific chimeric antigen receptor according to any one of claims 1 to 18.

### Claim 23 (depends on 21, 22)

An engineered immune cell according to claim 21 or 22, wherein said immune cell is a T-lymphocyte.

### Claim 24 (depends on 23)

An engineered immune cell according to claim 23, wherein said T-cell is from a primary cell or differentiated from stem cells, such as iPS cells.

### Claim 25 (depends on 23, 24)

An engineered immune cell according to claim 23 or 24, derived from inflammatory T-lymphocytes, cytotoxic T-lymphocytes or helper T-lymphocytes.

### Claim 26 (depends on 21, 22, 23, 24, 25)

An engineered immune cell according to any one of claims 21 to 25, wherein expression of TCR is reduced or suppressed in said immune cell.

### Claim 27 (depends on 26)

An engineered immune cell according to claim 26, wherein at least one gene encoding TCRalpha or TCRbeta has been inactivated in said cell.

### Claim 28 (depends on 27)

An engineered immune cell according to claim 27, wherein said at least one gene encoding TCRalpha or TCRbeta has been cleaved by a rare-cutting endonuclease.

### Claim 29 (depends on 27, 28)

An engineered immune cell according to claim 27 or 28, wherein the polynucleotide encoding said mesothelin specific CAR has been integrated at an endogenous locus under transcriptional control of an endogenous promoter, preferably at the TCRalpha or TCRbeta locus.

### Claim 30 (depends on 29)

An engineered immune cell according to claim 29, originating from a donor for allogeneic transplantation.

### Claim 31 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

An engineered immune cell according to any one of claims 21 to 30, wherein said cell is mutated to confer resistance to at least one immune suppressive drug, such as an anti-CD52 antibody.

### Claim 32 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

An engineered immune cell according to any one of claims 21 to 31, wherein said cell has been further mutated to confer resistance to at least one chemotherapy drug, in particular a purine analogue drug.

### Claim 33 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

An engineered immune cell according to any one of claims 21 to 32, wherein said cell has been mutated to improve its persistence or its lifespan into the patient, in particular into a gene encoding MHCI component(s) such as HLA or B2m.

### Claim 34 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

An engineered immune cell according to any one of claims 21 to 33, wherein said cell is mutated to improve its CAR-dependent immune activation, in particular to reduce or suppress the expression of immune checkpoint proteins and/or receptors thereof.

### Claim 35 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

An engineered immune cell according to any one of claims 21 to 34, wherein said mesothelin-specific chimeric antigen receptor (CAR) is co-expressed in said cell with another exogenous genetic sequence encoding an inhibitor or decoy of TGFbeta receptor.

### Claim 36 (depends on 35)

An engineered immune cell according to claim 35, wherein said decoy of TGFbeta receptor is a dominant negative TGFbeta receptor, such as one having at least 80% polypeptide sequence identity with SEQ ID NO.24.

### Claim 37 (depends on 36)

An engineered immune cell according to claim 36, wherein said cell comprises an exogenous polynucleotide comprising a first polynucleotide sequence encoding said mesothelin-specific CAR, a second polynucleotide encoding a 2A self-cleaving peptide, and a third polynucleotide encoding said dominant negative TGFbeta receptor.

### Claim 38 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

An engineered immune cell according to any one of claims 21 to 37, wherein said cell has at least one TGFbeta receptor gene expression reduced or inactivated.

### Claim 39 (depends on 38)

An engineered immune cell according to claim 38, wherein said TGFbeta receptor gene is TGFβRII.

### Claim 40 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

An engineered immune cell according to any one of claims 21 to 39, wherein said mesothelin-specific chimeric antigen receptor (CAR) is co-expressed in said cell with another exogenous genetic sequence selected from one encoding:
NK cell inhibitor, such as HLAG, HLAE or ULBP1;
CRS inhibitor, such as is a mutated IL6Ra, sGP130 or IL18-BP; or
Cytochrome(s) P450, CYP2D6-1, CYP2D6-2, CYP2C9, CYP3A4, CYP2C19 or CYP1A2, conferring hypersensitivity of said immune cells to a drug, such as cyclophosphamide and/or isophosphamide,
Dihydrofolate reductase (DHFR), inosine monophosphate dehydrogenase 2 (IMPDH2), calcineurin or methylguanine transferase (MGMT), mTORmut or Lckmut, conferring drug resistance
or a cytokine, such as IL-2, IL-12 and IL-15.
receptors, such as CCR2, CXCR2, or CXCR4;
a secreted inhibitor of Tumor Associated Macrophages (TAM), such as a CCR2/CCL2 neutralization agent, to enhance the therapeutic activity of the immune cells;

### Claim 41 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

An engineered immune cell according to claim 21 to 40, for use in therapy.

### Claim 42 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

An engineered immune cell according to any one of claims 21 to 41, for use as a medicament for the treatment of cancer.

### Claim 43 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

An engineered immune cell according to any one of claims 21 to 42, for use in therapy of a pre-malignant or malignant cancer condition characterized by mesothelin expressing cells.

### Claim 44 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

An engineered immune cell according to any one of claims 21 to 43, for use in therapy of a cancer condition, selected from oesophageal cancer, breast cancer, gastric cancer, cholangiocarcinoma, pancreatic cancer, colon cancer, Lung cancer, Thymic carcinoma, mesothelioma, ovarian cancer, and endometrial cancer.

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

A method for treating a patient having a condition characterized by mesothelin expressing cells, comprising the steps of:
Engineering immune cells from a donor to express a functional mesothelin specific chimeric antigen receptor (CAR) according to any one of claims 1 to 20:
Administrating said CAR positive engineered immune cells to a patient to eliminate cells expressing mesothelin.

### Claim 46 (depends on 45)

A method for treating a patient according to claim 45, comprising an additional treatment step in which the patient is lymphodepleted.

### Claim 47 (depends on 46)

A method for treating a patient according to claim 46, wherein said CAR positive engineered immune cells that eliminate cells expressing mesothelin is mutated to confer resistance to the lymphodepletion treatment.

### Claim 48 (depends on 47)

A method for treating a patient according to claim 47, wherein said CAR positive engineered immune cells that eliminate cells expressing mesothelin is mutated in its CD52 gene.
